Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A carcinoma that arises from the transitional epithelium of the ureter. It is associated with tobacco use and usually presents with gross or microscopic hematuria.
Biomarker and diagnostic research for ureter transitional cell carcinoma has been reported in the published literature.
18 clinical trials registered, 5 recruiting. Interventions under study include drug therapy, procedural interventions, biologic therapy, and other interventions. Pipeline includes 1 PHASE4, 3 PHASE3, 8 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04628767](https://clinicaltrials.gov/study/NCT04628767) |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 8:53 PM UTC
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer |
PHASE2 |
National Cancer Institute (NCI) |
RECRUITING |
[NCT05874921](https://clinicaltrials.gov/study/NCT05874921) | uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | — | UroGen Pharma Ltd. | RECRUITING |
[NCT05987241](https://clinicaltrials.gov/study/NCT05987241) | Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | PHASE2 | National Cancer Institute (NCI) | RECRUITING |
[NCT07087860](https://clinicaltrials.gov/study/NCT07087860) | Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers | PHASE2 | Mayo Clinic | RECRUITING |
[NCT06764095](https://clinicaltrials.gov/study/NCT06764095) | Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial | PHASE4 | Mayo Clinic | RECRUITING |
126 publications have been identified in PubMed for ureter transitional cell carcinoma. Research spans Clinical Trial Publication (27%), Case Report / Case Series (23%), and Epidemiology / Natural History (17%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 34 | 27% |
Patient case studies | 29 | 23% |
Disease patterns and progression | 22 | 17% |
Research summaries | 15 | 12% |
Testing and diagnosis research | 13 | 10% |
Laboratory research | 11 | 9% |
New treatment approaches | 2 | 2% |
Serrano P (2026). [PMID: 41939611](https://pubmed.ncbi.nlm.nih.gov/41939611/). *Cureus*. [Case Report / Case Series]
Xie J (2026). [PMID: 41540431](https://pubmed.ncbi.nlm.nih.gov/41540431/). *BMC Med*. [Epidemiology / Natural History]
Eichenauer R (2026). [PMID: 41916385](https://pubmed.ncbi.nlm.nih.gov/41916385/). *Aktuelle Urol*. [Epidemiology / Natural History]
Wu SY (2026). [PMID: 42086351](https://pubmed.ncbi.nlm.nih.gov/42086351/). *Can J Urol*. [Epidemiology / Natural History]
Huang T (2026). [PMID: 42094814](https://pubmed.ncbi.nlm.nih.gov/42094814/). *Oncol Lett*. [Case Report / Case Series]
Moryousef J (2026). [PMID: 41671923](https://pubmed.ncbi.nlm.nih.gov/41671923/). *Urol Oncol*. [Review / Meta-Analysis]
Gabriel PE (2026). [PMID: 42108360](https://pubmed.ncbi.nlm.nih.gov/42108360/). *Ann Surg Oncol*. [Clinical Trial Publication]
Yajima S (2026). [PMID: 41469226](https://pubmed.ncbi.nlm.nih.gov/41469226/). *Asian J Endosc Surg*. [Case Report / Case Series]
Eldesouki S (2026). [PMID: 42174561](https://pubmed.ncbi.nlm.nih.gov/42174561/). *BMC Urol*. [Case Report / Case Series]
Le NB (2026). [PMID: 41533515](https://pubmed.ncbi.nlm.nih.gov/41533515/). *Cell Rep*. [Basic Science / Preclinical]